Wedbush Comments on PepGen’s FY2028 Earnings (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at Wedbush raised their FY2028 earnings per share (EPS) estimates for PepGen in a report issued on Monday, December 16th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($2.08). Wedbush currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.84) per share.

Several other equities research analysts also recently weighed in on PEPG. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of PepGen in a research report on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Monday.

PepGen Stock Performance

NASDAQ:PEPG opened at $4.09 on Thursday. The firm has a 50-day simple moving average of $6.06 and a two-hundred day simple moving average of $10.42. The firm has a market cap of $133.32 million, a P/E ratio of -1.37 and a beta of 1.56. PepGen has a fifty-two week low of $2.90 and a fifty-two week high of $19.30.

Institutional Trading of PepGen

A number of large investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in PepGen by 318.7% in the third quarter. Barclays PLC now owns 21,971 shares of the company’s stock worth $189,000 after purchasing an additional 16,723 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of PepGen in the third quarter worth $130,000. Jane Street Group LLC increased its position in PepGen by 29.1% during the third quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock valued at $237,000 after acquiring an additional 6,254 shares during the last quarter. Wellington Management Group LLP lifted its holdings in PepGen by 76.9% in the third quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock valued at $346,000 after acquiring an additional 17,618 shares during the period. Finally, Janus Henderson Group PLC boosted its position in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after purchasing an additional 1,794,641 shares during the last quarter. 58.01% of the stock is currently owned by institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.